FDA and EMA Join Forces on Treatment of Gaucher Disease in Children - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA and EMA Join Forces on Treatment of Gaucher Disease in Children


FDA and the European Medicines Agency (EMA) released a draft joint proposal to facilitate research in the development of new drugs to treat Gaucher disease in children. The proposal, the result of consultation with various groups of stakeholders, facilitates an agreement between an FDA Pediatric Study Plan and an EMA Paediatric Investigation Plan and addresses the development of drugs for rare diseases in a reduced timeframe in a limited number of patients.

A number of drugs are under development for the treatment of Gaucher disease, a rare condition where specific chemical substances (glucocerebrosides) accumulate in certain cells throughout the body. The disease causes multiple symptoms, including neurological symptoms. According to EMA, there is a high need for new routes of treatment administration to reduce the treatment burden for children with the disease.

The joint FDA/EMA proposal suggests the extrapolation of efficacy from adults to children, including the use of modeling and simulation approaches, and multi-arm, multi-company clinical trials to determine the safety and efficacy of several new medicines and, at the same time, to reduce the number of children involved in the trials.

“The complementary approach proposed would not only facilitate the investigation of new medicines for rare diseases in children but also optimize the number of patients recruited, thereby reducing the burden on children and families,” explains Jordi Llinares Garcia, head of EMA’s Product Development Scientific Support Department, in a press release.

The agencies encourage sponsors who wish to incorporate these proposed approaches in their development plan to contact either EMA or FDA for scientific advice.

Source: European Medicines Agency

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here